HIKMA PHARMA LIMITED
Get an alert when HIKMA PHARMA LIMITED files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Cash
£50K
-8.7% vs 2023
Net assets
£34M
0% vs 2023
Employees
—
Average over period
Profit before tax
£24M
+531.9% vs 2023
Net assets
2-year trend · vs Unclassified median
Accounts
2-year trend · latest reflected 2024-12-31
| Metric | Trend | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Turnover | — | — | |
| Operating profit | — | — | |
| Profit before tax | £3,763,341 | £23,781,409 | |
| Net profit | £3,763,341 | £23,781,409 | |
| Cash | £54,403 | £49,660 | |
| Total assets less current liabilities | — | — | |
| Net assets | £33,590,608 | £33,590,584 | |
| Equity | £33,590,608 | £33,590,584 | |
| Average employees | — | — | |
| Wages | — | — |
Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers
Ratios
Computed from the line items above — sparklines read oldest → newest
| Ratio | Trend | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Current ratio | 6.59x | 6.59x |
Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.
Audit & accounting basis
- Accounting basis
- FRS 101
- Reporting scope
- Standalone (parent only)
- Audit opinion
- Unaudited (audit-exempt)
- Going concern
- Affirmed
“The Directors have assessed the ability of Hikma to provide that support and, on that basis, have concluded that the application of the going concern basis of preparation of the financial statements is appropriate.”
Group structure
- HIKMA PHARMA LIMITED · parent
- Hikma Investment LLC 100%
- Hikma Italia S.p.A 100%
- Hikma International Pharmaceuticals LLC 100%
- Arab Medical Containers LLC 100%
- Hikma Pharmaceuticals LLC 100%
- Arab Pharmaceutical Manufacturing PSC 100%
- SPA Al Dar Al Arabia pour la Fabrication de Medicaments 99.9%
- Hikma Pharma Algeria S.A.R.L. 99.62%
- Hikma Pharmaceuticals (Private Limited Foreign Company) 100%
- Hikma Care for Medicines and Medical Supplies Company 51%
- Hikma Pharmaceuticals LLC (Free Zone) 100%
- Savanna Pharmaceutical Industries Co. Ltd 100%
- Sofia Travel and Tourism 100%
- Specialized for Pharmaceutical Industries LLC 100%
- STE D'Industriee Pharmaceutique Ibn Al Baytar 100%
- APM Tunisie S.A.R.L. 100%
- STE Medicef 99.9%
- International Pharmaceutical Research Centre LLC 51%
- Pharma Ixir Co. Ltd 51%
Significant events
- “The Directors are not aware of any matter or circumstance arising since the end of the financial year that would significantly affect the operations of the Company or the results of its operations.”
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
4 active · 8 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| FCM TRUST LIMITED | Corporate Secretary | 2026-02-26 | — | — |
| AL KURDI, Areb | Director | 2022-08-15 | Oct 1974 | Jordanian |
| KHOURI, Bana | Director | 2022-02-11 | Apr 1983 | British |
| MIDDLEMIST, Helen | Director | 2022-07-18 | Sep 1981 | British |
Show 8 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| MIDDLEMIST, Helen | Secretary | 2022-07-29 | 2026-02-26 |
| SPEIRS, Peter Alexander | Secretary | 2011-12-19 | 2022-06-15 |
| ATWAL, Gurpal Singh | Director | 2011-12-19 | 2022-02-11 |
| CREASE, Thomas Michael | Director | 2013-07-18 | 2015-01-05 |
| HANSEN, Joanna Elizabeth | Director | 2022-06-15 | 2025-09-25 |
| HYDE, Jane Celia | Director | 2016-04-18 | 2018-10-09 |
| KNOWLES, Henry James | Director | 2011-12-19 | 2013-06-27 |
| SPEIRS, Peter Alexander | Director | 2011-12-19 | 2022-06-15 |
Ownership
Persons with significant control
Filing timeline
Last 20 of 39 total filings
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2026-04-20 | OSAP04 | officers | Appoint corporate secretary overseas company with appointment date | |
| 2026-03-27 | OSCH02 | other | Change company details overseas company with change details | |
| 2026-03-27 | OSTM02 | officers | Termination person secretary overseas company with name termination date | |
| 2025-10-06 | OSTM01 | officers | Termination person director overseas company with name termination date | |
| 2025-08-07 | AA | accounts | Accounts with accounts type full | |
| 2024-09-20 | OSCH03 | officers | Change person director overseas company with change date | |
| 2024-08-30 | AA | accounts | Accounts with accounts type full | |
| 2023-10-02 | AA | accounts | Accounts with accounts type group | |
| 2022-11-09 | AA | accounts | Accounts with accounts type full | |
| 2022-08-25 | OSAP01 | officers | Appoint person director overseas company with name appointment date | |
| 2022-08-09 | OSAP03 | officers | Appoint person secretary overseas company with appointment date | |
| 2022-08-03 | OSTM02 | officers | Termination person secretary overseas company with name termination date | |
| 2022-08-03 | OSTM01 | officers | Termination person director overseas company with name termination date | |
| 2022-08-03 | OSTM01 | officers | Termination person director overseas company with name termination date | |
| 2022-08-03 | OSAP01 | officers | Appoint person director overseas company with name appointment date | |
| 2022-08-03 | OSAP01 | officers | Appoint person director overseas company with name appointment date | |
| 2022-08-03 | OSAP01 | officers | Appoint person director overseas company with name appointment date | |
| 2021-05-19 | AA | accounts | Accounts with accounts type full | |
| 2020-11-17 | AA | accounts | Accounts with accounts type full | |
| 2019-01-27 | OSTM01 | officers | Termination person director overseas company with name termination date |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 5
- Capital events
- 0
- Officers appointed
- 1
- Officers resigned
- 2
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.
Year-on-year
FY2023 → FY2024 · period ending 2024-12-31 vs 2023-12-31
-
Turnover
—
Not reported
-
Cash
-8.7%
£54,403 £49,660
-
Net assets
0%
£33,590,608 £33,590,584
-
Employees
—
Not reported
-
Profit before tax
+531.9%
£3,763,341 £23,781,409
Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers